Core Viewpoint - Suzhou Beikang Medical has received approval from the National Medical Products Administration (NMPA) for its Gems culture medium (embryo handling liquid VitBase), marking a significant milestone in the localization of reproductive liquids in China and demonstrating the company's full industry chain capability from international acquisition to domestic registration [1][3][4]. Group 1: Product Approval and Significance - The approval of VitBase is the first registration certificate among the 11 products in the GEMS series, laying the foundation for the subsequent localization of the entire product line in China [4]. - This approval reflects the national support for the innovative transformation of overseas medical products and positions Beikang Medical as one of the few companies globally with CE, FDA, and TGA certifications for reproductive liquids [3][4]. Group 2: Market Impact and Benefits - The introduction of the Gems culture medium is expected to enhance supply chain security, reduce reliance on imports, and promote a more reasonable pricing system, benefiting more patients [4]. - The product is based on over 30 years of clinical experience from the globally recognized Sydney IVF center, ensuring high product quality while improving accessibility and supply chain reliability [3][4]. Group 3: Future Outlook - Beikang Medical aims to provide a more stable culture environment for embryos and improve the success rates of IVF in China through the localization of Gems culture medium [8]. - The company plans to continue developing and registering high-end reproductive medical products, gradually achieving full-chain domestic substitution [8].